Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$7.67 USD
+0.01 (0.13%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $7.66 -0.01 (-0.13%) 7:50 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OTLK 7.67 +0.01(0.13%)
Will OTLK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OTLK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OTLK
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
OTLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
Other News for OTLK
Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
Outlook Therapeutics: Worth A Good Strong Look After CRL
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
Outlook gets EU approval for Lytenava for wet AMD
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD